HomeBUSINESS
BUSINESS

Shionogi Grabs Rights to Rohto’s Cell-Based Hepatic Cirrhosis Therapy
(Sep.14.2018)

Shionogi has acquired exclusive rights to develop and commercialize Rohto Pharmaceutical’s investigational cell-based hepatic cirrhosis therapy ADR-001 in Japan, the two companies said on September 13 ...
(LOG IN FOR FULL STORY)

News Calendar